MICAL2 promotes breast cancer cell migration by maintaining epidermal growth factor receptor (EGFR) stability and EGFR/P38 signalling activation

2017 ◽  
Vol 222 (2) ◽  
pp. e12920 ◽  
Author(s):  
Y. Wang ◽  
W. Deng ◽  
Y. Zhang ◽  
S. Sun ◽  
S. Zhao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Cell Migration ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Growth Factor Receptor ◽  
Cancer Cell Migration ◽  
Epidermal Growth

scholarly journals Photonic modulation of epidermal growth factor receptor halts receptor activation and cancer cell migration

2018 ◽  
Vol 11 (9) ◽  
pp. e201700323
Author(s):  
Cláudia M. Botelho ◽  
Odete Gonçalves ◽  
Rogério Marques ◽  
Viruthachalam Thiagarajan ◽  
Henrik Vorum ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Cell Migration ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Cell ◽  
Growth Factor Receptor ◽  
Receptor Activation ◽  
Cancer Cell Migration ◽  
Epidermal Growth

scholarly journals Intratumoral Estrogen Receptor Heterogeneity of Expression in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer as Evaluated by a Brightfield Multiplex Assay

2019 ◽  
Vol 67 (8) ◽  
pp. 563-574 ◽  
Author(s):  
Shinobu Masuda ◽  
Hiroaki Nitta ◽  
Brian D. Kelly ◽  
Wenjun Zhang ◽  
Michael Farrell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Growth Factor Receptor ◽  
Multiplex Assay ◽  
Epidermal Growth

Breast cancer (BC) is a heterogeneous disease with evolving genetic alterations and expressions of receptor proteins. Intratumoral heterogeneity (ITH) is considered to be a resistance factor in response to targeted therapies. The current single-slide, single-marker immunohistochemistry techniques cannot accurately assess ITH at the individual cancer cell level. In this study, we develop a novel brightfield multiplex assay to simultaneously assess estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) protein markers, together with the HER2 gene and the centromere of chromosome 17 ( CEP17) copy numbers, using a single tissue section. The data presented herein demonstrate heterogeneous cancer cell subpopulations in 11 HER2-positive/ER-positive (HER2+/ER+) tumors among 33 BCs analyzed immunohistochemically (HER2 score of 2+ or 3+). The predominant cancer cell subpopulation was HER2+/ER− (50.18%), followed by HER2+/ER+ (39.05%), HER2−/ER+ (4.26%), ER− with HER2 microheterogeneity cancer cells (3.58%), and ER+ with HER2 microheterogeneity cancer cells (2.93%). The three other tumor subtypes, namely, HER2−/ER+, HER2+/ER−, and HER2−/ER−, were more homogeneous, representing 82.59%, 99.22%, and 100% of cancer cells, respectively. This novel assay revealed that HER2+ cancer cells were more predominant than ER+ cancer cells in HER2+/ER+ tumors and provided new insights toward our understanding of BC carcinogenesis.

Sign in / Sign up

Export Citation Format

Share Document